Richard S. Judson
Technik-/Wissenschafts-/F&E-Leiter bei Genaissance Pharmaceuticals, Inc.
Aktive Positionen von Richard S. Judson
| Unternehmen | Position | Beginn | Ende |
|---|---|---|---|
Genaissance Pharmaceuticals, Inc.
 Genaissance Pharmaceuticals, Inc. BiotechnologyHealth Technology Genaissance Pharmaceuticals, Inc. develops and uses genetic information to diagnostic and therapeutic products. The company was founded by Kevin L. Rakin and Gualberto Ruano in 1992 and is headquartered in New Haven, CT. | Technik-/Wissenschafts-/F&E-Leiter | 01.02.1999 | - |
Karriereverlauf von Richard S. Judson
Ehemalige bekannte Positionen von Richard S. Judson
| Unternehmen | Position | Beginn | Ende |
|---|---|---|---|
CuraGen Corp.
 CuraGen Corp. Pharmaceuticals: MajorHealth Technology CuraGen Corp. develops protein, antibody and small molecule pharmaceutical products. The firm focuses on the development of CR011-vcMMAE, a Phase II clinical trial drug for the treatment of patients with metastatic melanoma and breast cancer. The company was founded in 1991 and is headquartered in Branford, CT. | Corporate Officer/Principal | 01.01.1997 | 01.02.1999 |
Ausbildung von Richard S. Judson
| Rice University | Undergraduate Degree |
| Princeton University | Doctorate Degree |
Statistik
International
| Vereinigte Staaten | 5 |
Operativ
| Chief Tech/Sci/R&D Officer | 1 |
| Undergraduate Degree | 1 |
| Doctorate Degree | 1 |
Sektoral
| Health Technology | 3 |
| Consumer Services | 3 |
Besetzte Positionen
Aktive
Inaktive
Börsennotierte Unternehmen
Private Unternehmen
Unternehmensverbindungen
| Private Unternehmen | 2 |
|---|---|
Genaissance Pharmaceuticals, Inc.
Genaissance Pharmaceuticals, Inc. BiotechnologyHealth Technology Genaissance Pharmaceuticals, Inc. develops and uses genetic information to diagnostic and therapeutic products. The company was founded by Kevin L. Rakin and Gualberto Ruano in 1992 and is headquartered in New Haven, CT. | Health Technology |
CuraGen Corp.
CuraGen Corp. Pharmaceuticals: MajorHealth Technology CuraGen Corp. develops protein, antibody and small molecule pharmaceutical products. The firm focuses on the development of CR011-vcMMAE, a Phase II clinical trial drug for the treatment of patients with metastatic melanoma and breast cancer. The company was founded in 1991 and is headquartered in Branford, CT. | Health Technology |
- Börse
- Insiders
- Richard S. Judson
- Erfahrung
